Online first
Research paper (original)
Published online: 2024-04-26
HPV vaccination coverage in the European Region
1
, 1, 1
, 1, 1
DOI: 10.5603/njo.99853
Abstract
Introduction. Human papillomavirus (HPV) is an established cause of cervical cancer and other HPV-related diseases. This study aims to analyze the variation in coverage by HPV vaccination programs, particularly within the European Region countries, and explore possible health outcomes.
Material and methods. A comprehensive literature review and analysis of epidemiological data were conducted, focusing on HPV vaccination coverage rates, the implementation of vaccination programs, and their outcomes across the EU/EEA. The study examined various vaccination models, including school-based and health center-based programs, to understand their effectiveness in achieving high vaccination coverage and the associated reduction in HPV-related disease burden.
Results. The study's analysis identified significant variations in HPV vaccination coverage across the EU/EEA. School-based vaccination programs, in particular, were found to be highly effective in reaching the target population, achieving coverage rates significantly higher than those observed in countries relying on health center-based or mixed-model vaccination strategies.
Conclusions. HPV vaccination programs have played a crucial role in reducing the burden of HPV-related diseases. These programs' success largely depends on achieving high vaccination coverage, which is more effectively realized through school-based vaccination strategies.
Keywords: human papillomavirusHPV vaccinationcancer preventioncervical cancerschool-based interventioncoverage
References
- Schiller JT, Frazer IH, Lowry DR. Human papillomavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA. ed. Vaccines, 7th edition. Saunders/Elsevier, Philadelphia, PA 2017: 430–455.
- World Health Organisation. Cervical cancer. 2022. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer (10.11.2023).
- zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2(5): 342–350.
- Hall M, Simms K, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019; 4(1): e19–e27.
- Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394(10197): 497–509.
- Poljak M, Seme K, Maver P, et al. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Central and Eastern Europe. Vaccine. 2013; 31: H59–H70.
- Topazian H, Kundu D, Peebles K, et al. HPV Vaccination Recommendation Practices among Adolescent Health Care Providers in 5 Countries. J Pediatr Adolesc Gynecol. 2018; 31(6): 575–582.e2.
- A Cervical Cancer-Free Future: First-Ever Global Commitment to Eliminate Cancer. WHO press release.
- WHO’s Launch of the Global Strategy to Accelerate the Elimination of Cervical Cancer.
- https://szczepienia.pzh.gov.pl/faq/gdzie-w-europie-prowadzone-sa-programy-szczepien-przeciw-hpv-dziewczat-i-chlopcow/.
- https://szczepienia.pzh.gov.pl/dla-lekarzy/szczepienia-hpv/programy-szczepien-przeciw-hpv/.
- Which countries include human papillomavirus (HPV) vaccines in their vaccination schedules? 2006 to 2021. https://ourworldindata.org/grapher/human-papillomavirus-vaccine-immunization-schedule?tab=table.
- OECD iLibrary. https://www.oecd-ilibrary.org/social-issues-migration-health/eu-country-cancer-profiles_55f07000-en (10.11.2023).
- Krajowy Rejestr Nowotworów 2022. http://onkologia.org.pl/raporty/#mapa_polski (10.11.2023).
- McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014; 74(11): 1253–1283.
- Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30 Suppl 5: F12–F23.
- Martín-Hernán F, Sánchez-Hernández JG, Cano J, et al. Oral cancer, HPV infection and evidence of sexual transmission. Med Oral Patol Oral Cir Bucal. 2013; 18(3): e439–e444.
- https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet.
- Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine. 2017; 35(13): 1729–1732.
- World Health Organization. Electronic address: sageexecsec@who.int. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017; 92(19): 241–268.
- Drolet M, Bénard É, Pérez N, et al. HPV Vaccination Impact Study Group. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15(5): 565–580.
- Cocchio S, Baldovin T, Bertoncello C, et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017; 17(1): 249.
- Guerra FM, Rosella LC, Dunn S, et al. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment. Vaccine. 2016; 34(39): 4678–4683.
- Bollerup S, Baldur-Felskov B, Blomberg M, et al. Significant reduction in the incidence of genital warts in young men five years into the Danish human papillomavirus vaccination program for girls and women. Sex Transm Dis. 2016; 43(4): 238–242.
- Lurie S, Mizrachi Y, Chodick G, et al. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. Gynecol Oncol. 2017; 146(2): 299–304.
- Navarro-Illana E, López-Lacort M, Navarro-Illana P, et al. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Vaccine. 2017; 35(25): 3342–3346.
- Hariri S, Schuler MS, Naleway AL, et al. Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States. Am J Epidemiol. 2018; 187(2): 298–305.
- Lamb F, Herweijer E, Ploner A, et al. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. BMJ Open. 2017; 7(6): e015021.
- Gargano W, Unger ER, Gui L, et al. Prevalence of genital human papillomavirus in males United States 2013–2014. J Infect Dis. 2017; 215(7): 1070–1079.
- Kahn J, Widdice L, Ding L, et al. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clin Infect Dis. 2016; 63(10): 1281–1287.
- Tanton C, Mesher D, Beddows S, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017; 3: 36–41.
- Brotherton J, Bloem P. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2018; 47: 42–58.
- Walling EB, Benzoni N, Dornfeld J, et al. Interventions to Improve HPV Vaccine Uptake: A Systematic Review. Pediatrics. 2016; 138(1).
- Niccolai LM, Hansen CE. Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review. JAMA Pediatr. 2015; 169(7): 686–692.
- Barnard M, Cole AC, Ward L, et al. Interventions to increase uptake of the human papillomavirus vaccine in unvaccinated college students: A systematic literature review. Prev Med Rep. 2019; 14: 100884.
- Nguyen-Huu NH, Thilly N, Derrough T, et al. HPV Policy working group. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine. 2020; 38(6): 1315–1331.